Trial
NCT02170025
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
Merck Sharp & Dohme LLC
Condition
Cystic Fibrosis
Intervention
Riociguat (Adempas, BAY63-2521)
Why stopped
Study was terminated after completion of Part 1, because Part 2 was no longer appropriate.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-07